Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia

The Link Between Pharmacodynamics and Physiologically Based Pharmacokinetic Models

(2013) V Perera et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

CYP1A2 and coffee intake and the modifying effect of sex, age, and smoking

(2012) Eline M Rodenburg et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Achieving the Promise of Personalized Medicine

(2012) K S Reynolds   CLINICAL PHARMACOLOGY & THERAPEUTICS

Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array

(2012) J A Johnson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenomics Knowledge for Personalized Medicine

(2012) M Whirl-Carrillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe

(2012) Vidya Perera et al.   CURRENT DRUG METABOLISM

Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension

(2012) Idris Guessous et al.   HUMAN MOLECULAR GENETICS

Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans

(2012) Vidya Perera et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking

(2012) Maria Dobrinas et al.   Pharmacogenetics and Genomics

Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia

(2012) Marco Ferrari et al.   PSYCHIATRY RESEARCH

Population Pharmacokinetic Modeling of Risperidone and 9-Hydroxyrisperidone to Estimate CYP2D6 Subpopulations in Children and Adolescents

(2012) Catherine M. T. Sherwin et al.   THERAPEUTIC DRUG MONITORING

Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?

(2011) Erin Schwenger et al.   CLINICAL PHARMACOKINETICS

Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility

(2011) M Dobrinas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics

(2011) Vidya Perera et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Drug Metabolism in Older People--A Key Consideration in Achieving Optimal Outcomes With Medicines

(2011) A. J. McLachlan et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia

(2011) Hakan Balibey et al.   KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY

Unknown

(2011) Jeffrey Wickliffe et al.   MOLECULAR MEDICINE

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011

(2011) C. Hiemke et al.   PHARMACOPSYCHIATRY

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia

(2011) Giorgio Colombo   Neuropsychiatric Disease and Treatment

The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine

(2010) Tore Haslemo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives

(2010) Haya Ascher-Svanum et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacogenetics of CYP1A2, Novel Polymorphisms and Haplotypes in Three Distinct Asian Populations

(2010) Joanne Siok Liu Lim et al.   Drug Metabolism and Pharmacokinetics

Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism

(2010) Natasa Djordjevic et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients

(2010) Roza Ghotbi et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

High Correlation Between Serum and Cerebrospinal Fluid Olanzapine Concentrations in Patients With Schizophrenia or Schizoaffective Disorder Medicating With Oral Olanzapine as the Only Antipsychotic Drug

(2010) Elisabeth Skogh et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Cytochrome P450-mediated metabolism in the human gut wall

(2010) Kirstin Thelen et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Coffee consumption and CYP1A2 genotype in relation to bone mineral density of the proximal femur in elderly men and women: a cohort study

(2010) Helena Hallström et al.   Nutrition & Metabolism

Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation

(2010) John S. Bradley et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme

(2010) Sarah L. Browning et al.   Pharmacogenetics and Genomics

Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression

(2010) B Brito Palma et al.   PHARMACOGENOMICS JOURNAL

Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver

(2010) Kathrin Klein et al.   Frontiers in Pharmacology

Polymorphism of human cytochrome P450 enzymes and its clinical impact

(2009) Shu-Feng Zhou et al.   DRUG METABOLISM REVIEWS

CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension

(2009) Paolo Palatini et al.   JOURNAL OF HYPERTENSION

Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population

(2009) Arzu Gunes et al.   PHARMACOGENOMICS

Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers

(2009) Roza Ghotbi et al.   PHARMACOGENOMICS JOURNAL

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome

(2009) B Laika et al.   PHARMACOGENOMICS JOURNAL

CYP1A2 genotype and rheumatoid arthritis in Koreans

(2009) Marilyn C. Cornelis et al.   RHEUMATOLOGY INTERNATIONAL

The Relationship Between the Response of Clinical Symptoms and Plasma Olanzapine Concentration, Based on Pharmacogenetics

(2009) Motohiro Nozawa et al.   THERAPEUTIC DRUG MONITORING

Coffee Consumption and CYP1A2*1F Genotype Modify Age at Breast Cancer Diagnosis and Estrogen Receptor Status

(2008) E. Bageman et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Free Drug Metabolic Clearance in Elderly People

(2008) Jennifer M Butler et al.   CLINICAL PHARMACOKINETICS

Reduced Activities of Cytochrome P450 1A2 and Xanthine Oxidase in Children With Growth Hormone Deficiency

(2008) MJ Kennedy et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice

(2008) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Sex-specific differences in CYP450 isoforms in humans

(2008) Marissa J Scandlyn et al.   Expert Opinion on Drug Metabolism & Toxicology

Effectiveness and Tolerability of Olanzapine in the Treatment of Adolescents with Schizophrenia and Related Psychotic Disorders: Results from a Large, Prospective, Open-Label Study

(2008) Ralf W. Dittmann et al.   JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Sex, Race, and Smoking Impact Olanzapine Exposure

(2008) Kristin L. Bigos et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms

(2008) Arzu Gunes et al.   PHARMACOGENOMICS